World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
39944
World Ranking
13424
National Ranking
6827

Christopher R. Flowers publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Christopher R. Flowers sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 774 publications — 86th percentile

86% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Christopher R. Flowers D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Christopher R. Flowers sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Christopher R. Flowers is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their work primarily spans the field of Medicine, with a focus on several key subfields including Pathology and Forensic Medicine, Oncology, Genetics, Immunology, and Molecular Biology.

The researcher's scientific output covers a variety of main topics, notably:

  • Lymphoma Diagnosis and Treatment
  • CAR-T cell therapy research
  • Chronic Lymphocytic Leukemia Research
  • Viral-associated cancers and disorders
  • CNS Lymphoma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Cancer Genomics and Diagnostics

Christopher R. Flowers has contributed frequently to several prominent publication venues. These include:

  • Blood
  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • Blood Advances
  • Leukemia & lymphoma/Leukemia and lymphoma

Some of the recent papers involving Christopher R. Flowers are:

  • "Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society" (2020), published in CA A Cancer Journal for Clinicians
  • "International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI" (2020), published in Blood
  • "Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial" (2024), published in Nature Medicine
  • "Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Guideline Update" (2023), published in Journal of Clinical Oncology
  • "Bridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma" (2020), published in Blood Advances

Their work often involves collaboration with several frequent co-authors:

  • Loretta J. Nastoupil
  • Jason R. Westin
  • Sairah Ahmed
  • Sattva S. Neelapu
  • Ranjit Nair

Best Publications

  • Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society

    Kevin C. Oeffinger;Elizabeth T. H. Fontham;Ruth Etzioni;Abbe Herzig

  • Colorectal cancer screening for average-risk adults: 2018 guideline update from the American Cancer Society

    Andrew M.D. Wolf;Elizabeth T.H. Fontham;Timothy R. Church;Christopher R. Flowers

  • American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

    Gary H. Lyman;Alok A. Khorana;Anna Falanga;Daniel Clarke-Pearson

  • Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

    Nigel S Key;Alok A Khorana;Nicole M Kuderer;Kari Bohlke

  • Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014

    Gary H. Lyman;Gary H. Lyman;Kari Bohlke;Alok A. Khorana;Nicole M. Kuderer

  • PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

    Ajay K. Gopal;Ajay K. Gopal;Brad S. Kahl;Sven de Vos;Nina D. Wagner-Johnston

  • 2016 US lymphoid malignancy statistics by World Health Organization subtypes.

    Lauren R. Teras;Carol E. DeSantis;James R. Cerhan;Lindsay M. Morton

  • Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma.

    Anupama Reddy;Jenny Zhang;Nicholas S. Davis;Andrea B. Moffitt

  • American Cancer Society lung cancer screening guidelines

    Richard Wender;Elizabeth T.H. Fontham;Ermilo Barrera;Ermilo Barrera;Graham A. Colditz

  • Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

    Carla Casulo;Michelle Byrtek;Keith L. Dawson;Xiaolei Zhou

  • Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society

    Elizabeth T.H. Fontham;Andrew M.D. Wolf;Timothy R. Church;Ruth Etzioni;Ruth Etzioni

  • Genetic heterogeneity of diffuse large B-cell lymphoma

    Jenny Zhang;Vladimir Grubor;Cassandra L. Love;Anjishnu Banerjee

  • The genetic landscape of mutations in Burkitt lymphoma

    Cassandra Love;Zhen Sun;Dereje Jima;Guojie Li

  • Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Laurie H. Sehn;Alex F. Herrera;Christopher R. Flowers;Manali K. Kamdar

  • Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline

    Christopher R. Flowers;Jerome Seidenfeld;Eric J. Bow;Clare Karten

  • Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update

    Randy A Taplitz;Erin B Kennedy;Eric J Bow;Jennie Crews

  • Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis.

    Adam M Petrich;Mitul Gandhi;Borko Jovanovic;Jorge J Castillo

  • Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities.

    Mohamed L. Sorror;Michael B. Maris;Barry Storer;Brenda M. Sandmaier

  • Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors.

    Razvan Diaconescu;Christopher R. Flowers;Barry Storer;Mohamed L. Sorror

  • Follicular Lymphoma in the United States: First Report of the National LymphoCare Study

    Jonathan W. Friedberg;Michael D. Taylor;James R. Cerhan;Christopher R. Flowers

Frequent Co-Authors

Sagar Lonial
Sagar Lonial Emory University
Jonathan W. Friedberg
Jonathan W. Friedberg University of Rochester
James R. Cerhan
James R. Cerhan Mayo Clinic
Gilles Salles
Gilles Salles Memorial Sloan Kettering Cancer Center
Luis Fayad
Luis Fayad The University of Texas MD Anderson Cancer Center
Ian W. Flinn
Ian W. Flinn Sarah Cannon Research Institute
Andrew D. Zelenetz
Andrew D. Zelenetz Memorial Sloan Kettering Cancer Center
John P. Leonard
John P. Leonard Cornell University
Michael Wang
Michael Wang Argonne National Laboratory

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in Medicine but prefer alternative routes or the flexibility of online learning, there are several related degrees and career pathways to explore. For nurses aiming to advance their careers affordably, cheap online dnp programs provide a pathway to leadership roles and higher salaries without the need for a traditional, on-campus experience.

Aspiring pharmacists can consider a 3 year online pharmd, which offers an accelerated and flexible approach to earning a pharmacy doctorate. For those interested in healthcare administration and managing patient data, an online mhi (Master's in Health Information) enables you to develop vital skills in a growing field, often at a lower cost than in-person programs.

If you want to enter the healthcare industry quickly and with minimal investment, the average cost of medical billing and coding program indicates entry-level opportunities that can be pursued affordably and almost entirely online. Each of these online degree options provides unique benefits and can lead to rewarding careers in healthcare, offering flexibility for busy students or working professionals.

Best Scientists Citing Christopher R. Flowers

Trending Scientists